Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value

$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

KPIs

Operating metrics that drive Abbott Laboratories's business · fiscal year ends December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q3 2026 2026-09-30	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31

Continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M)($M)2		2,100	2,000	2,000	2,000	1,900	1,700	1,800	1,700	1,600	1,500	1,400
CGM (FreeStyle Libre) — Organic / Comparable Sales Growth (%)(%)	7.7%	9.5%	7.6%	12.2%	17.2%	19.6%	21.6%	22.8%	20.7%	20.4%	23.3%
CGM (FreeStyle Libre) — Reported Sales Growth (%)(%)	7.3%	11.0%	14.2%	15.0%	20.5%	21.4%	18.3%	22.7%	19.1%	18.4%	22.4%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M)($M)5	2,185	2,188	2,080	2,133	2,057	1,981	1,827	1,863	1,725	1,648	1,569	1,552
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Organic / Comparable Sales Growth (%)(%)	6.7%	9.0%	7.4%	11.7%	16.2%	18.5%	19.8%	20.6%	19.1%	18.2%	20.7%	20.7%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Reported Sales Growth (%)(%)	6.2%	10.5%	13.8%	14.5%	19.3%	20.2%	16.5%	20.1%	17.1%	15.8%	19.5%	22.0%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Foreign Exchange Impact on Sales Growth (%)(%)				2.8%	3.1%	1.7%	-3.3%	-0.5%	-2.0%	-2.4%	-1.2%	1.3%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — U.S. Revenue ($M)($M)2	872	862	822	843	796	794	748	734	673	637	589	601
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) U.S. — Organic / Comparable Sales Growth (%)(%)	9.4%	8.6%	9.8%	14.9%	18.4%	24.5%	27.1%	22.0%	23.6%	26.3%	22.8%	28.3%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) U.S. — Reported Sales Growth (%)(%)	9.4%	8.6%	9.8%	14.9%	18.4%	24.5%	27.1%	22.0%	23.6%	26.3%	22.8%	28.3%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — International Revenue ($M)($M)2	1,313	1,326	1,258	1,290	1,261	1,187	1,079	1,129	1,052	1,011	980	951
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Organic / Comparable Sales Growth (%)(%)	4.9%	9.2%	5.7%	9.6%	14.7%	14.7%	15.4%	19.7%	16.5%	13.7%	19.6%	16.2%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Reported Sales Growth (%)(%)	4.2%	11.7%	16.6%	14.2%	19.9%	17.5%	10.1%	18.8%	13.3%	10.0%	17.6%	18.4%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Worldwide Revenue ($M)($M)5	873	861	788	730	705	700	629	643	610	627	587	593
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Organic / Comparable Sales Growth (%)(%)	15.5%	13.4%	12.5%	12.5%	13.7%	10.3%	9.9%	8.8%	14.3%	16.7%	18.4%	21.2%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Reported Sales Growth (%)(%)	15.0%	14.0%	16.7%	13.5%	15.6%	11.5%	7.3%	8.3%	12.2%	13.3%	16.2%	21.5%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Foreign Exchange Impact on Sales Growth (%)(%)				1.0%	1.9%	1.2%	-2.6%	-0.5%	-2.1%	-3.4%	-2.2%	0.3%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — U.S. Revenue ($M)($M)2	429	420	378	340	322	322	299	300	285	287	269	279
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) U.S. — Organic / Comparable Sales Growth (%)(%)	18.1%	15.9%	13.7%	13.1%	13.2%	12.2%	11.1%	7.7%	15.8%	16.8%	13.1%	15.0%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) U.S. — Reported Sales Growth (%)(%)	18.1%	15.9%	13.7%	13.1%	13.2%	12.2%	11.1%	7.7%	15.8%	16.8%	13.1%	15.0%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — International Revenue ($M)($M)2	444	441	410	390	383	378	330	343	325	340	318	314
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) International — Organic / Comparable Sales Growth (%)(%)	13.1%	11.1%	11.2%	11.9%	14.1%	8.8%	8.8%	9.8%	13.0%	16.7%	23.0%	27.3%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) International — Reported Sales Growth (%)(%)	12.2%	12.3%	19.6%	13.9%	17.6%	10.9%	4.0%	8.8%	9.2%	10.5%	18.9%	28.0%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Worldwide Revenue ($M)($M)5	592	597	578	675	635	636	577	609	558	564	515	498
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Organic / Comparable Sales Growth (%)(%)	6.9%	5.7%	6.8%	8.7%	11.3%	11.7%	14.7%	22.6%	16.5%	15.6%	13.0%	11.4%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Reported Sales Growth (%)(%)	1.9%	2.7%	9.0%	10.8%	13.6%	13.0%	11.9%	22.4%	14.6%	13.2%	11.7%	12.9%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Foreign Exchange Impact on Sales Growth (%)(%)				2.1%	2.3%	1.3%	-2.8%	-0.2%	-1.9%	-2.4%	-1.3%	1.5%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — U.S. Revenue ($M)($M)2	228	225	224	304	297	289	282	290	270	258	233	231
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) U.S. — Organic / Comparable Sales Growth (%)(%)	-2.3%	-0.9%	-3.6%	4.8%	10.1%	12.2%	20.9%	25.7%	21.1%	17.9%	10.8%	7.9%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) U.S. — Reported Sales Growth (%)(%)	-11.1%	-9.8%	-9.5%	4.8%	10.1%	12.2%	20.9%	25.7%	21.1%	17.9%	10.8%	7.9%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — International Revenue ($M)($M)2	364	372	354	371	338	347	295	319	288	306	282	267
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Organic / Comparable Sales Growth (%)(%)	13.5%	10.2%	15.0%	12.3%	12.4%	11.4%	9.6%	20.0%	12.6%	13.8%	14.8%	14.7%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Reported Sales Growth (%)(%)	12.2%	12.1%	25.2%	16.3%	16.9%	13.7%	4.6%	19.5%	9.2%	9.4%	12.5%	17.6%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Worldwide Revenue ($M)($M)5	752	743	684	705	686	673	585	624	597	607	562	582
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Organic / Comparable Sales Growth (%)(%)	10.0%	9.5%	12.5%	11.5%	13.0%	9.8%	6.1%	7.2%	7.0%	5.9%	7.5%	12.1%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Reported Sales Growth (%)(%)	9.7%	10.4%	17.0%	13.1%	15.0%	10.9%	4.0%	7.1%	5.9%	4.2%	6.8%	13.3%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Foreign Exchange Impact on Sales Growth (%)(%)				1.6%	2.0%	1.1%	-2.1%	-0.1%	-1.1%	-1.7%	-0.7%	1.2%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — U.S. Revenue ($M)($M)2	380	377	339	340	350	340	304	303	288	292	271	285
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Organic / Comparable Sales Growth (%)(%)	9.0%	10.7%	11.5%	12.8%	21.1%	16.5%	12.3%	6.0%	6.0%	8.5%	4.5%	12.0%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Reported Sales Growth (%)(%)	9.0%	10.7%	11.5%	12.8%	21.1%	16.5%	12.3%	6.0%	6.0%	8.5%	4.5%	12.0%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — International Revenue ($M)($M)2	372	366	345	365	336	333	281	321	309	315	291	297
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Organic / Comparable Sales Growth (%)(%)	11.0%	8.3%	13.5%	10.2%	5.5%	3.6%	0.3%	8.4%	7.9%	3.7%	10.3%	12.1%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Reported Sales Growth (%)(%)	10.4%	10.0%	22.9%	13.4%	9.3%	5.7%	-3.7%	8.2%	5.7%	0.4%	9.0%	14.5%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Worldwide Revenue ($M)($M)5	387	401	389	375	366	368	339	331	322	321	305	301
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Organic / Comparable Sales Growth (%)(%)	6.0%	8.7%	12.2%	12.1%	12.1%	14.0%	12.4%	9.6%	14.4%	8.9%	8.4%	15.4%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Reported Sales Growth (%)(%)	5.8%	9.0%	14.6%	13.2%	13.3%	14.7%	11.4%	9.9%	14.0%	8.6%	8.5%	16.6%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Foreign Exchange Impact on Sales Growth (%)(%)				1.1%	1.2%	0.7%	-1.0%	0.3%	-0.4%	-0.3%	0.1%	1.2%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — U.S. Revenue ($M)($M)2	303	313	292	283	280	282	262	253	252	244	237	227
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) U.S. — Organic / Comparable Sales Growth (%)(%)	8.4%	10.9%	11.4%	11.7%	10.7%	15.8%	10.6%	11.5%	16.7%	7.7%	8.7%	13.6%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) U.S. — Reported Sales Growth (%)(%)	8.4%	10.9%	11.4%	11.7%	10.7%	15.8%	10.6%	11.5%	16.7%	7.7%	8.7%	13.6%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — International Revenue ($M)($M)2	84	88	97	92	86	86	77	78	70	77	68	74
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) International — Organic / Comparable Sales Growth (%)(%)	-1.6%	1.3%	14.9%	13.4%	17.2%	8.4%	19.1%	4.1%	6.6%	12.8%	7.1%	21.4%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) International — Reported Sales Growth (%)(%)	-2.7%	3.0%	25.2%	17.9%	22.6%	11.2%	14.3%	5.0%	5.2%	11.4%	7.7%	26.6%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Worldwide Revenue ($M)($M)5	786	803	777	783	745	757	710	725	699	724	689	677
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Organic / Comparable Sales Growth (%)(%)	5.7%	5.1%	4.9%	6.5%	4.7%	3.5%	5.7%	6.8%	4.9%	1.2%	5.8%	4.5%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Reported Sales Growth (%)(%)	5.4%	6.1%	9.5%	8.0%	6.6%	4.5%	3.0%	7.1%	3.9%	1.3%	11.7%	12.0%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Foreign Exchange Impact on Sales Growth (%)(%)				1.5%	1.9%	1.0%	-2.7%	0.3%	-1.0%	-2.0%	-1.0%	1.1%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — U.S. Revenue ($M)($M)2	290	294	291	287	280	283	268	269	258	275	254	245
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) U.S. — Organic / Comparable Sales Growth (%)(%)	3.4%	3.9%	8.6%	6.5%	8.5%	3.0%	5.5%	9.7%	2.8%	-0.8%	-1.8%	-2.5%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) U.S. — Reported Sales Growth (%)(%)	3.4%	3.9%	8.6%	6.5%	8.5%	3.0%	5.5%	9.7%	2.8%	4.3%	16.4%	14.8%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — International Revenue ($M)($M)2	496	509	486	496	465	474	442	456	441	449	435	432
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) International — Organic / Comparable Sales Growth (%)(%)	7.1%	5.8%	2.7%	6.6%	2.5%	3.8%	5.8%	5.2%	6.2%	2.5%	9.9%	8.3%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) International — Reported Sales Growth (%)(%)	6.7%	7.5%	10.0%	8.9%	5.5%	5.4%	1.6%	5.7%	4.5%	-0.4%	9.1%	10.4%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Worldwide Revenue ($M)($M)5	251	260	243	274	254	254	228	257	236	243	226	240
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Organic / Comparable Sales Growth (%)(%)	-1.1%	1.2%	4.1%	5.6%	6.8%	4.3%	2.2%	8.4%	5.2%	8.2%	17.4%	18.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Reported Sales Growth (%)(%)	-1.2%	2.0%	6.8%	6.5%	7.6%	4.6%	1.0%	7.7%	3.8%	7.0%	15.3%	18.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Foreign Exchange Impact on Sales Growth (%)(%)				0.9%	0.8%	0.3%	-1.2%	-0.7%	-1.4%	-1.2%	-2.1%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — U.S. Revenue ($M)($M)2	185	189	177	208	196	193	176	204	190	192	181	197
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Organic / Comparable Sales Growth (%)(%)	-5.6%	-2.1%	0.7%	1.9%	3.3%	0.4%	-2.8%	4.2%	0.8%	3.7%	16.8%	20.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Reported Sales Growth (%)(%)	-5.6%	-2.1%	0.7%	1.9%	3.3%	0.4%	-2.8%	4.2%	0.8%	3.7%	16.8%	20.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — International Revenue ($M)($M)2	66	71	66	66	58	61	52	53	46	51	45	43
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Organic / Comparable Sales Growth (%)(%)	13.9%	11.3%	15.5%	19.6%	21.2%	18.7%	22.7%	27.8%	25.7%	28.4%	19.6%	10.2%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Reported Sales Growth (%)(%)	13.6%	14.7%	27.2%	23.8%	24.9%	20.4%	16.3%	23.9%	17.8%	21.7%	9.8%	10.2%
Medical Devices Segment Total — Worldwide Revenue ($M)($M)8	5,826	5,853	5,539	5,675	5,448	5,369	4,895	5,052	4,747	4,734	4,453	4,443
Medical Devices Segment Total — Organic / Comparable Sales Growth (%)(%)	7.8%	8.4%	8.5%	10.4%	12.5%	12.2%	12.6%	14.0%	13.3%	12.1%	14.3%	15.4%
Medical Devices Segment Total — Reported Sales Growth (%)(%)	6.9%	9.0%	13.2%	12.3%	14.8%	13.4%	9.9%	13.7%	11.7%	10.2%	14.2%	17.5%
Medical Devices Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)				1.9%	2.3%	1.2%	-2.7%	-0.3%	-1.6%	-2.2%	-1.2%	1.0%
Medical Devices Segment Total — U.S. Revenue ($M)($M)2	2,687	2,680	2,523	2,605	2,521	2,503	2,339	2,353	2,216	2,185	2,034	2,065
Medical Devices Segment Total U.S. — Organic / Comparable Sales Growth (%)(%)	7.6%	8.0%	8.7%	10.7%	13.8%	14.6%	15.0%	14.0%	14.2%	13.5%	12.1%	15.5%
Medical Devices Segment Total U.S. — Reported Sales Growth (%)(%)	6.6%	7.0%	7.9%	10.7%	13.8%	14.6%	15.0%	14.0%	14.2%	14.2%	14.4%	17.6%
Medical Devices Segment Total — International Revenue ($M)($M)2	3,139	3,173	3,016	3,070	2,927	2,866	2,556	2,699	2,531	2,549	2,419	2,378
Medical Devices Segment Total International — Organic / Comparable Sales Growth (%)(%)	8.0%	8.7%	8.3%	10.1%	11.3%	10.1%	10.5%	14.0%	12.5%	10.9%	16.1%	15.4%
Medical Devices Segment Total International — Reported Sales Growth (%)(%)	7.2%	10.7%	18.0%	13.7%	15.6%	12.4%	5.7%	13.5%	9.6%	7.0%	14.0%	17.5%
Medical Devices — Remaining Performance Obligations / Contract Backlog ($M)($M)		455	429	444	436	427	423	440	466	493	495	478
Medical Devices — Segment Research & Development Expense ($M)($M)		470	444	460	462	430	401	391	408	379	368
Medical Devices — Segment Property & Equipment Additions ($M)($M)		185	147	217	140	145	156	186	151	158	135

Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Worldwide Revenue ($M)($M)7	1,438	1,418	1,272	1,461	1,364	1,358	1,177	1,387	1,314	1,329	1,205	1,370
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Organic / Comparable Sales Growth (%)(%)	5.4%	3.2%	3.3%	3.6%	2.2%	1.6%	0.9%	3.8%	4.3%	8.6%	5.9%	9.1%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Reported Sales Growth (%)(%)	5.4%	4.4%	8.1%	5.3%	3.8%	2.2%	-2.3%	1.3%		2.8%	2.0%	8.4%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Foreign Exchange Impact on Sales Growth (%)(%)				1.7%	1.6%	0.6%	-3.2%	-2.5%	-4.3%	-5.8%	-3.9%	-0.7%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — U.S. Revenue ($M)($M)2	389	377	347	376	366	351	332	363	332	327	310	326
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) U.S. — Organic / Comparable Sales Growth (%)(%)	6.3%	7.5%	4.5%	3.6%	10.4%	7.3%	7.1%	11.9%	4.8%	5.3%	7.7%	8.8%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) U.S. — Reported Sales Growth (%)(%)	6.3%	7.5%	4.5%	3.6%	10.4%	7.3%	7.1%	11.6%	4.5%	5.1%	7.3%	8.3%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — International Revenue ($M)($M)2	1,049	1,041	925	1,085	998	1,007	845	1,024	982	1,002	895	1,044
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) International — Organic / Comparable Sales Growth (%)(%)	5.1%	1.7%	2.8%	3.6%	-0.6%	-0.3%	-1.3%	1.5%	4.4%	9.9%	5.7%	10.0%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) International — Reported Sales Growth (%)(%)	5.1%	3.4%	9.5%	5.9%	1.6%	0.5%	-5.6%	-1.9%	-1.5%	2.1%	0.2%	8.4%
Core Laboratory — Organic Sales Growth Excl. COVID-19 Testing (%)(%)								4.0%	4.5%	8.8%	6.2%	9.7%
Core Laboratory — COVID-19 Testing Sales ($M)($M)2								2	3	2	3	4
Core Laboratory — U.S. COVID-19 Testing Sales ($M)($M)								1	1	1	1	1
Core Laboratory — International COVID-19 Testing Sales ($M)($M)								1	2	1	2	3
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Worldwide Revenue ($M)($M)3	968	919	96			0	0
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Organic / Comparable Sales Growth (%)(%)	13.8%	13.3%	13.4%
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — U.S. Revenue ($M)($M)1	938	890	93
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) U.S. — Organic / Comparable Sales Growth (%)(%)	13.9%	13.3%	13.2%
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — International Revenue ($M)($M)1	30	29	3
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) International — Organic / Comparable Sales Growth (%)(%)	12.1%	13.8%	19.2%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Worldwide Revenue ($M)($M)4	899	755	812			815	877
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Organic / Comparable Sales Growth (%)(%)	0.9%	-8.0%	-9.6%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Reported Sales Growth (%)(%)	1.1%	-7.3%	-7.4%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — U.S. Revenue ($M)($M)2	526	393	465
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Organic / Comparable Sales Growth (%)(%)	1.1%	-14.5%	-13.8%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Reported Sales Growth (%)(%)	1.1%	-14.5%	-13.8%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — International Revenue ($M)($M)2	373	362	347
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) International — Organic / Comparable Sales Growth (%)(%)	0.7%	0.5%	-2.7%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) International — Reported Sales Growth (%)(%)	1.0%	2.0%	2.8%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Worldwide Revenue ($M)($M)7				697	600	544	613	849	824	583	741	862
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Organic / Comparable Sales Growth (%)(%)				-18.1%	-27.7%	-6.8%	-16.1%	-1.0%	-3.0%	-19.8%	-38.7%	-49.2%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Reported Sales Growth (%)(%)				-17.8%	-27.3%	-6.7%	-17.3%	-1.6%	-4.4%	-21.3%	-39.5%	-49.3%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Foreign Exchange Impact on Sales Growth (%)(%)				0.3%	0.4%	0.1%	-1.2%	-0.6%	-1.4%	-1.5%	-0.8%	-0.1%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M)($M)2				445	373	321	399	554	560	345	481	543
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Organic / Comparable Sales Growth (%)(%)				-19.7%	-33.5%	-7.1%	-16.9%	30.0%	-1.0%	-6.6%	6.9%	-29.2%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Reported Sales Growth (%)(%)				-19.7%	-33.5%	-7.1%	-16.9%	2.1%	-0.2%	-32.1%	-46.9%	-55.3%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — International Revenue ($M)($M)2				252	227	223	214	295	264	238	260	319
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) International — Organic / Comparable Sales Growth (%)(%)				-14.9%	-15.6%	-6.3%	-14.6%	-0.6%	2.8%	11.0%	3.5%	18.6%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) International — Reported Sales Growth (%)(%)				-14.1%	-14.2%	-6.1%	-17.9%	-7.9%	-12.2%	2.1%	-18.3%	-34.4%
Rapid Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)(%)								16.4%	0.4%	0.4%	5.6%	-13.7%
Rapid Diagnostics — COVID-19 Testing Sales ($M)($M)2								172	259	97	197	277
Rapid Diagnostics — U.S. COVID-19 Testing Sales ($M)($M)								132	203	66	149	218
Rapid Diagnostics — International COVID-19 Testing Sales ($M)($M)								40	56	31	48	59
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Worldwide Revenue ($M)($M)7				141	131	123	122	137	128	127	129	153
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Organic / Comparable Sales Growth (%)(%)				1.1%	0.8%	-3.4%	-3.5%	-10.2%	-2.1%	-9.4%	-11.7%	-14.9%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Reported Sales Growth (%)(%)				3.2%	2.6%	-2.7%	-5.9%	-10.5%	-3.6%	-10.3%	-11.9%	-14.6%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Foreign Exchange Impact on Sales Growth (%)(%)				2.1%	1.8%	0.7%	-2.4%	-0.3%	-1.5%	-0.9%	-0.2%	0.3%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — U.S. Revenue ($M)($M)2				39	36	35	40	38	37	33	42	44
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Organic / Comparable Sales Growth (%)(%)				2.9%	-1.5%	5.5%	-4.4%	-7.2%	4.5%	-19.0%	6.2%	-12.6%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Reported Sales Growth (%)(%)				2.9%	-1.5%	5.5%	-4.4%	-13.9%	-2.8%	-22.5%	-10.6%	-27.7%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M)($M)2				102	95	88	82	99	91	94	87	109
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Organic / Comparable Sales Growth (%)(%)				0.4%	1.7%	-6.5%	-3.1%	-7.5%	0.8%		-3.6%	8.2%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Reported Sales Growth (%)(%)				3.3%	4.3%	-5.6%	-6.7%	-9.1%	-3.9%	-4.9%	-12.5%	-7.8%
Molecular Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)(%)								-7.4%	1.8%	-5.6%	-0.8%	1.7%
Molecular Diagnostics — COVID-19 Testing Sales ($M)($M)2								2	3	3	4	7
Molecular Diagnostics — U.S. COVID-19 Testing Sales ($M)($M)								1	2	2	3	5
Molecular Diagnostics — International COVID-19 Testing Sales ($M)($M)								1	1	1	1	2
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Worldwide Revenue ($M)($M)5				158	158	148	142	147	146	156	139	149
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Organic / Comparable Sales Growth (%)(%)				7.1%	7.8%	-5.2%	3.2%	-1.4%	4.6%	10.0%	3.6%	13.0%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Reported Sales Growth (%)(%)				7.5%	8.2%	-5.1%	2.4%	-1.3%	4.4%	9.9%	3.7%	13.6%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Foreign Exchange Impact on Sales Growth (%)(%)				0.4%	0.4%	0.1%	-0.8%	0.1%	-0.2%	-0.1%	0.1%	0.6%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — U.S. Revenue ($M)($M)2				107	111	104	100	100	103	107	98	107
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) U.S. — Organic / Comparable Sales Growth (%)(%)				6.5%	7.9%	-2.0%	1.5%	-6.1%	6.0%	8.1%	5.6%	20.7%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) U.S. — Reported Sales Growth (%)(%)				6.5%	7.9%	-2.0%	1.5%	-6.1%	6.0%	8.1%	5.6%	20.7%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — International Revenue ($M)($M)2				51	47	44	42	47	43	49	41	42
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Organic / Comparable Sales Growth (%)(%)				8.3%	7.7%	-12.1%	7.3%	10.7%	1.3%	14.5%	-0.8%	-2.9%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Reported Sales Growth (%)(%)				9.8%	8.9%	-11.9%	4.4%	11.0%	0.7%	14.1%	-0.6%	-1.0%
Global COVID-19 Testing-Related Sales ($M)($M)2				89	69	55	84	176	265	102	204	288
Diagnostics Segment — Organic Sales Growth Excl. COVID-19 Testing (%)(%)				-0.2%	0.4%	0.8%		6.1%	3.3%	5.9%	5.4%	2.2%
Diagnostics Segment — COVID-19 Testing YoY Impact on Sales Growth (%)(%)				-3.4%	-8.2%	-2.2%		-5.1%	-1.9%	-7.4%	-20.9%	-24.5%
Diagnostics Segment Total — Worldwide Revenue ($M)($M)8	3,305	3,092	2,180	2,457	2,253	2,173	2,054	2,520	2,412	2,195	2,214	2,534
Diagnostics Segment Total — Organic / Comparable Sales Growth (%)(%)	6.4%	2.9%	1.8%	-3.6%	-7.8%	-1.4%	-4.9%	1.0%	1.4%	-1.5%	-15.5%	-22.3%
Diagnostics Segment Total — Reported Sales Growth (%)(%)	46.7%	42.3%	6.1%	-2.5%	-6.6%	-1.0%	-7.2%	-0.6%	-1.5%	-5.3%	-17.6%	-22.7%
Diagnostics Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)				1.1%	1.2%	0.4%	-2.3%	-1.6%	-2.9%	-3.8%	-2.1%	-0.4%
Diagnostics Segment Total — U.S. Revenue ($M)($M)2	1,853	1,660	905	967	886	811	871	1,055	1,032	812	931	1,020
Diagnostics Segment Total U.S. — Organic / Comparable Sales Growth (%)(%)	8.4%	4.0%	2.0%	-8.4%	-14.1%	-0.1%	-6.4%	15.9%	2.4%	-0.3%	7.0%	-10.7%
Diagnostics Segment Total U.S. — Reported Sales Growth (%)(%)	109.2%	104.8%	3.8%	-8.4%	-14.1%	-0.1%	-6.4%	3.5%	1.8%	-15.5%	-30.3%	-38.8%
Diagnostics Segment Total — International Revenue ($M)($M)2	1,452	1,432	1,275	1,490	1,367	1,362	1,183	1,465	1,380	1,383	1,283	1,514
Diagnostics Segment Total International — Organic / Comparable Sales Growth (%)(%)	4.0%	1.6%	1.6%	-0.2%	-3.1%	-2.2%	-3.8%	0.8%	3.8%	9.5%	4.4%	10.9%
Diagnostics Segment Total International — Reported Sales Growth (%)(%)	6.2%	5.1%	7.8%	1.8%	-1.0%	-1.5%	-7.8%	-3.4%	-3.8%	1.9%	-5.1%	-6.0%
Diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M)($M)		6,200	6,200	6,100	6,000	5,900	5,700	5,500	5,300	4,800	4,500	4,400
Diagnostics — Segment Research & Development Expense ($M)($M)		268	155	147	150	154	151	174	165	162	155
Diagnostics — Segment Property & Equipment Additions ($M)($M)		157	128	292	168	166	135	283	183	169	123

Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Worldwide Revenue ($M)($M)6	1,063	1,025	953	902	977	1,054	1,041	1,000	955	1,059	1,009	985
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Organic / Comparable Sales Growth (%)(%)	8.7%	-3.1%	-9.7%	-10.1%	2.4%	0.2%	4.9%	2.5%	-2.7%	5.0%	10.5%	14.5%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Reported Sales Growth (%)(%)	8.8%	-2.7%	-8.5%	-9.8%	2.3%	-0.4%	3.2%	1.5%	-4.5%	3.4%	9.2%	11.8%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Foreign Exchange Impact on Sales Growth (%)(%)				0.3%	-0.1%	-0.6%	-1.7%	-1.0%	-1.8%	-1.6%	-1.3%	-0.5%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — U.S. Revenue ($M)($M)2	577	525	511	463	520	587	588	562	568	564	514	505
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) U.S. — Organic / Comparable Sales Growth (%)(%)	11.0%	-10.7%	-13.0%	-17.7%	-8.4%	4.2%	14.2%	11.3%	12.2%	11.3%	12.0%	11.4%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) U.S. — Reported Sales Growth (%)(%)	11.0%	-10.7%	-13.0%	-17.7%	-8.4%	4.2%	14.2%	11.3%	12.2%	11.3%	12.0%	11.4%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — International Revenue ($M)($M)2	486	500	442	439	457	467	453	438	387	495	495	480
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) International — Organic / Comparable Sales Growth (%)(%)	6.0%	6.4%	-5.3%	-0.3%	18.2%	-4.5%	-4.8%	-6.7%	-18.0%	-1.0%	8.9%	17.9%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) International — Reported Sales Growth (%)(%)	6.4%	7.3%	-2.6%	0.3%	17.9%	-5.7%	-8.4%	-8.9%	-21.6%	-4.4%	6.4%	12.3%
Preterm Infant Formula (NEC) Litigation Reserve Balance ($M)($M)		0	0				0		0
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Worldwide Revenue ($M)($M)5	1,199	1,119	1,064	1,038	1,176	1,158	1,105	1,129	1,111	1,091	1,059	1,053
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Organic / Comparable Sales Growth (%)(%)	1.8%	-4.0%	-5.9%	-8.2%	5.4%	6.6%	8.7%	11.4%	9.1%	9.9%	5.3%	13.4%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Reported Sales Growth (%)(%)	2.0%	-3.4%	-3.6%	-8.1%	5.8%	6.1%	4.4%	7.4%	3.6%	3.7%	1.5%	12.5%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Foreign Exchange Impact on Sales Growth (%)(%)				0.1%	0.4%	-0.5%	-2.9%	-2.3%	-4.4%	-5.4%	-3.8%	-0.9%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — U.S. Revenue ($M)($M)2	381	346	333	343	368	370	367	366	382	369	364	355
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) U.S. — Organic / Comparable Sales Growth (%)(%)	3.5%	-6.4%	-9.2%	-6.3%	-3.8%	0.2%	4.8%	8.1%	11.5%	0.8%	3.0%	4.0%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) U.S. — Reported Sales Growth (%)(%)	3.5%	-6.4%	-9.2%	-6.3%	-3.8%	0.2%	1.1%	3.2%	7.9%	-1.2%	3.0%	4.0%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — International Revenue ($M)($M)2	818	773	731	695	808	788	738	763	729	722	695	698
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) International — Organic / Comparable Sales Growth (%)(%)	1.0%	-2.8%	-4.3%	-9.1%	10.2%	9.8%	10.6%	13.0%	8.0%	14.7%	6.4%	18.9%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) International — Reported Sales Growth (%)(%)	1.3%	-2.0%	-0.9%	-8.9%	10.9%	9.2%	6.1%	9.5%	1.5%	6.4%	0.8%	17.4%
Nutritional Products Segment Total — Worldwide Revenue ($M)($M)7	2,262	2,144	2,017	1,940	2,153	2,212	2,146	2,129	2,066	2,150	2,068	2,038
Nutritional Products Segment Total — Organic / Comparable Sales Growth (%)(%)	4.9%	-3.6%	-7.7%	-9.1%	4.0%	3.4%	6.8%	7.1%	3.4%	7.5%	7.7%	13.9%
Nutritional Products Segment Total — Reported Sales Growth (%)(%)	5.1%	-3.1%	-6.0%	-8.9%	4.2%	2.9%	3.8%	4.5%	-0.3%	3.5%	5.1%	12.2%
Nutritional Products Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)				0.2%	0.2%	-0.5%	-2.4%	-1.7%	-3.1%	-3.6%	-2.6%	-0.7%
Nutritional Products Segment Total — U.S. Revenue ($M)($M)2	958	871	844	806	888	957	955	928	950	933	878	860
Nutritional Products Segment Total U.S. — Organic / Comparable Sales Growth (%)(%)	7.9%	-9.0%	-11.6%	-13.2%	-6.5%	2.6%	10.4%	10.0%	11.9%	6.9%	8.1%	8.2%
Nutritional Products Segment Total U.S. — Reported Sales Growth (%)(%)	7.9%	-9.0%	-11.6%	-13.2%	-6.5%	2.6%	8.8%	8.0%	10.4%	6.0%	8.1%	8.2%
Nutritional Products Segment Total — International Revenue ($M)($M)2	1,304	1,273	1,173	1,134	1,265	1,255	1,191	1,201	1,116	1,217	1,190	1,178
Nutritional Products Segment Total International — Organic / Comparable Sales Growth (%)(%)	2.8%	0.6%	-4.7%	-5.9%	13.0%	4.0%	4.2%	4.9%	-2.6%	7.9%	7.4%	18.5%
Nutritional Products Segment Total International — Reported Sales Growth (%)(%)	3.1%	1.4%	-1.5%	-5.6%	13.3%	3.1%	0.1%	2.0%	-7.9%	1.7%	3.0%	15.3%
Nutritional Products — Segment Research & Development Expense ($M)($M)		54	54	52	55	54	52	51	53	53	52
Nutritional Products — Segment Property & Equipment Additions ($M)($M)		46	40	71	71	81	79	100	106	103	73

Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Worldwide Revenue ($M)($M)4	1,195	1,164	1,089	1,046	1,097	1,059	965	948	994	988	928	918
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Organic / Comparable Sales Growth (%)(%)	10.9%	10.7%	9.4%	8.7%	11.1%	8.7%	9.3%	8.8%	5.4%	8.8%	15.4%	11.4%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Reported Sales Growth (%)(%)	9.0%	9.8%	12.9%	10.3%	10.3%	7.3%	4.0%	3.3%	0.7%	-0.2%	1.7%	0.5%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Foreign Exchange Impact on Sales Growth (%)(%)				1.6%	-0.8%	-1.4%	-5.3%	-5.5%	-4.7%	-9.0%	-13.7%	-10.9%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — International Revenue ($M)($M)2	1,195	1,164	1,089	1,046	1,097	1,059	965	948	994	988	928	918
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) International — Organic / Comparable Sales Growth (%)(%)	10.9%	10.7%	9.4%	8.7%	11.1%	8.7%	9.3%	8.8%	5.4%	8.8%	15.4%	11.4%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) International — Reported Sales Growth (%)(%)	9.0%	9.8%	12.9%	10.3%	10.3%	7.3%	4.0%	3.3%	0.7%	-0.2%	1.7%	0.5%
Other Emerging & International Markets — Worldwide Revenue ($M)($M)4	419	335	337	336	414	324	295	320	412	306	298	304
Other Emerging & International Markets — Organic / Comparable Sales Growth (%)(%)	1.6%	2.1%	7.9%	1.9%	-2.5%	4.5%	3.1%	7.8%	11.2%	5.7%	8.2%	0.8%
Other Emerging & International Markets — Reported Sales Growth (%)(%)	1.1%	3.7%	14.1%	5.0%	0.6%	5.9%	-1.2%	5.2%	8.1%	3.1%	7.6%	0.4%
Other Emerging & International Markets — Foreign Exchange Impact on Sales Growth (%)(%)				3.1%	3.1%	1.4%	-4.3%	-2.6%	-3.1%	-2.6%	-0.6%	-0.4%
Other Emerging & International Markets — International Revenue ($M)($M)2	419	335	337	336	414	324	295	320	412	306	298	304
Other Emerging & International Markets International — Organic / Comparable Sales Growth (%)(%)	1.6%	2.1%	7.9%	1.9%	-2.5%	4.5%	3.1%	7.8%	11.2%	5.7%	8.2%	0.8%
Other Emerging & International Markets International — Reported Sales Growth (%)(%)	1.1%	3.7%	14.1%	5.0%	0.6%	5.9%	-1.2%	5.2%	8.1%	3.1%	7.6%	0.4%
Established Pharmaceutical Products Segment Total — Worldwide Revenue ($M)($M)6	1,614	1,499	1,426	1,382	1,511	1,383	1,260	1,268	1,406	1,294	1,226	1,222
Established Pharmaceutical Products Segment Total — Organic / Comparable Sales Growth (%)(%)	8.4%	8.7%	9.0%	7.0%	7.1%	7.7%	7.8%	8.5%	7.0%	8.1%	13.7%	8.8%
Established Pharmaceutical Products Segment Total — Reported Sales Growth (%)(%)	6.8%	8.4%	13.2%	9.0%	7.5%	6.9%	2.7%	3.8%	2.7%	0.6%	3.1%	0.5%
Established Pharmaceutical Products Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)				2.0%	0.4%	-0.8%	-5.1%	-4.7%	-4.3%	-7.5%	-10.6%	-8.3%
Established Pharmaceutical Products Segment Total — International Revenue ($M)($M)2	1,614	1,499	1,426	1,382	1,511	1,383	1,260	1,268	1,406	1,294	1,226	1,222
Established Pharmaceutical Products Segment Total International — Organic / Comparable Sales Growth (%)(%)	8.4%	8.7%	9.0%	7.0%	7.1%	7.7%	7.8%	8.5%	7.0%	8.1%	13.7%	8.8%
Established Pharmaceutical Products Segment Total International — Reported Sales Growth (%)(%)	6.8%	8.4%	13.2%	9.0%	7.5%	6.9%	2.7%	3.8%	2.7%	0.6%	3.1%	0.5%
Established Pharmaceuticals — Segment Research & Development Expense ($M)($M)		48	41	49	42	43	42	45	46	44	41
Established Pharmaceuticals — Segment Property & Equipment Additions ($M)($M)		36	20	59	38	39	33	65	52	37	29

Total Company Consolidated Net Sales — Worldwide Revenue ($M)($M)6	13,013	12,593	11,164	11,459	11,369	11,142	10,358	10,974	10,635	10,377	9,964	10,241
Total Company Consolidated Net Sales — Organic / Comparable Sales Growth (%)(%)	7.0%	4.8%	3.7%	3.0%	5.5%	6.9%	6.9%	8.8%	7.6%	7.4%	4.7%	2.1%
Total Company Consolidated Net Sales — Reported Sales Growth (%)(%)	14.5%	13.0%	7.8%	4.4%	6.9%	7.4%	4.0%	7.2%	4.9%	4.0%	2.2%	1.5%
Total Company Consolidated Net Sales — Foreign Exchange Impact on Sales Growth (%)(%)				1.4%	1.4%	0.5%	-2.8%	-1.4%	-2.5%	-3.5%	-2.9%	-0.8%
Total Company Consolidated Net Sales — U.S. Revenue ($M)($M)2	5,504	5,216	4,274	4,383	4,299	4,276	4,168	4,341	4,202	3,934	3,846	3,949
Total Company Consolidated Net Sales U.S. — Organic / Comparable Sales Growth (%)(%)	7.9%	3.5%	2.5%	0.9%	2.3%	8.7%	8.8%	13.5%	11.0%	9.0%	10.0%	7.1%
Total Company Consolidated Net Sales U.S. — Reported Sales Growth (%)(%)	28.0%	22.0%	2.5%	0.9%	2.3%	8.7%	8.4%	10.0%	10.1%	4.7%	-2.1%	-6.4%
Total Company Consolidated Net Sales — International Revenue ($M)($M)2	7,509	7,377	6,890	7,076	7,070	6,866	6,190	6,633	6,433	6,443	6,118	6,292
Total Company Consolidated Net Sales International — Organic / Comparable Sales Growth (%)(%)	6.4%	5.8%	4.6%	4.3%	7.6%	5.8%	5.7%	8.1%	6.5%	9.4%	11.3%	13.4%
Total Company Consolidated Net Sales International — Reported Sales Growth (%)(%)	6.2%	7.5%	11.3%	6.7%	9.9%	6.6%	1.2%	5.4%	1.7%	3.6%	5.2%	7.2%
Total Company — Organic Sales Growth Excl. COVID-19 Testing (%)(%)				3.8%	7.5%	7.5%		10.1%	8.2%	9.3%	10.8%	11.0%
Non-GAAP Adjusted Diluted Earnings Per Share ($/share)($)2	1.42	1.31	1.15	1.50	1.30	1.26	1.09	1.34	1.21	1.14	0.98	1.19
GAAP Diluted Earnings Per Share — Reconciliation Table ($/share)($)	0.53	0.53	0.61	1.01	0.94	1.01	0.76	5.27	0.94	0.74	0.70	0.91
Specified Items Impact on Diluted EPS ($/share)($)	0.89	0.78	0.54	0.49	0.36	0.25	0.33		0.27	0.40	0.28	0.28
Non-GAAP Adjusted Net Earnings ($M)($M)7	2,477	2,290	2,022	2,630	2,278	2,213	1,919	2,349	2,119	2,003	1,729	2,094
GAAP Net Earnings — Reconciliation Table ($M)($M)	920	928	1,077	1,776	1,644	1,779	1,325	9,229	1,646	1,302	1,225	1,594
Specified Items After-Tax Net Impact ($M)($M)	1,557	1,362	945	854	634	434	594	-6,880	473	701	504	500
Non-GAAP Adjusted Earnings Before Taxes ($M)($M)	2,920	2,701	2,385	3,086	2,728	2,650	2,298	2,763	2,492	2,356	2,035	2,435
Non-GAAP Adjusted Gross Margin ($M)($M)	7,448	7,307	6,284	6,543	6,344	6,346	5,918	6,240	5,983	5,809	5,547	5,722
Non-GAAP Adjusted Research & Development Expense ($M)($M)	892	867	743	706	730	705	689	690	694	657	663	622
Non-GAAP Adjusted Selling, General & Administrative Expense ($M)($M)	3,505	3,597	3,267	2,875	3,004	3,090	3,051	2,886	2,890	2,879	2,925	2,689
Intangible Assets Amortization Expense ($M)($M)5	841	658	422	422	420	420	420	465	470	471	472	481
Forecasted Annual Intangible Amortization — Year 1 ($M)($M)		2,300	2,300	1,500	1,500	1,500	1,500	1,700	1,700	1,700	1,700	1,900
Forecasted Annual Intangible Amortization — Year 2 ($M)($M)		1,800	1,800	1,200	1,200	1,200	1,200	1,500	1,600	1,600	1,600	1,700
Forecasted Annual Intangible Amortization — Year 3 ($M)($M)		1,700	1,700	650	700	700	700	1,200	1,300	1,300	1,300	1,600
Forecasted Annual Intangible Amortization — Year 4 ($M)($M)		1,500	1,500	608	600	600	600	668	700	700	700	1,300
Forecasted Annual Intangible Amortization — Year 5 ($M)($M)				363				605				700
Effective Tax Rate — Non-GAAP Adjusted (%)(%)1	15.2%	15.2%	15.2%	14.8%	16.5%	16.5%	16.5%	15.0%	15.0%	15.0%	15.0%	14.0%
Effective Tax Rate — GAAP Reported (%)(%)	25.3%	39.1%	25.6%	24.7%	24.6%	17.3%	25.5%	-354.6%	15.2%	19.0%	14.7%	11.2%
Quarterly Common Dividend Declared ($/share)($)	0.63	0.63	0.63	0.63	0.59	0.59	0.59	0.59	0.55	0.55	0.55	0.55
Total Inventories Net ($M)($M)3		7,315	6,989	6,488	6,708	6,954	6,639	6,194	6,813	6,814	6,827	6,570
Finished Goods Inventory ($M)($M)		4,512	4,274	3,976	4,130	4,319	4,063	3,700	4,173	4,060	4,063	3,946
Work in Process Inventory ($M)($M)		1,023	994	904	961	962	890	840	877	880	881	807
Raw Materials Inventory ($M)($M)		1,780	1,721	1,608	1,617	1,673	1,686	1,654	1,763	1,874	1,883	1,817
Property, Plant & Equipment — Gross Carrying Value ($M)($M)5		26,469	25,737	25,222	24,816	24,472	23,418	22,740	22,857	22,061	22,055	21,933
Machinery & Equipment — Gross ($M)($M)				17,571				15,517				15,179
Buildings — Gross ($M)($M)				4,543				4,207				4,161
Construction in Progress ($M)($M)				2,567				2,488				2,064
Land ($M)($M)				541				528				529
Accumulated Depreciation ($M)($M)		13,657	13,360	13,406	13,312	13,077	12,486	12,082	12,236	11,828	11,948	11,779
Common Shares Repurchased — Value ($M)($M)1		1,040	18	301	303	1	24	369	752	0	22	304
Common Shares Repurchased — Volume (Million Shares)(M)		0	0	0	0	0	0	0	0	0	0	0
Defined Benefit Pension Plans — Projected Benefit Obligation ($M)($M)2				9,880				9,450				10,030
Defined Benefit Pension Plans — Fair Value of Plan Assets ($M)($M)				16,247				14,143				13,085
Post-Retirement Medical & Dental Plans — Benefit Obligation ($M)($M)				1,386				1,166				1,181

Abbott India Limited — Revenue from Operations (INR Crores)9		1,814	1,710	1,724	1,757	1,738	1,605	1,614	1,633	1,558	1,439	1,437
Abbott India — Operating Profit / EBITDA (INR Crores)		522	481	463	502	446	429	436	439	391	330	388
Abbott India — Operating Profit Margin (%)(%)		29.0%	28.0%	27.0%	29.0%	26.0%	27.0%	27.0%	27.0%	25.0%	23.0%	27.0%
Abbott India — Operating Expenses (INR Crores)		1,291	1,229	1,261	1,255	1,293	1,176	1,178	1,194	1,167	1,109	1,049
Abbott India — Other / Treasury Income (INR Crores)		75	76	70	70	73	76	72	60	67	81	56
Abbott India — Depreciation & Amortization (INR Crores)		20	19	19	19	19	18	18	18	18	18	18
Abbott India — Profit Before Tax (INR Crores)		572	531	509	546	493	483	488	479	437	390	422
Abbott India — Effective Tax Rate (%)(%)		25.0%	26.0%	26.0%	24.0%	26.0%	24.0%	26.0%	25.0%	25.0%	26.0%	26.0%
Abbott India — Net Profit (INR Crores)		429	395	376	415	366	367	361	359	328	287	311
Abbott India — Earnings Per Share (INR / Share)		202	186	177	195	172	173	170	169	154	135	146
Abbott India Limited — Number of Registered Shareholders4	75,769	78,320	75,866	75,801	71,199	67,584	69,934	67,892	69,449	71,588	69,382	72,252
Abbott India — Promoter (Abbott Parent) Shareholding (%)(%)	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%
Abbott India — Domestic Institutional Investors (DIIs) Shareholding (%)(%)	9.0%	8.8%	8.9%	9.0%	9.1%	9.2%	8.9%	9.0%	9.0%	8.8%	8.9%	8.7%
Abbott India — Foreign Institutional Investors (FIIs) Shareholding (%)(%)	0.4%	0.4%	0.3%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Abbott India — Public / Retail Shareholding (%)(%)	15.6%	15.9%	15.8%	15.8%	15.7%	15.7%	15.9%	15.9%	15.9%	16.0%	15.9%	16.1%

U.S. FDA 510(k) Device Clearances — Abbott5	6	8	2	5	9	8	7	5	4	5	2	5
U.S. FDA 510(k) Device Clearances — Total U.S. MedTech Industry	855	923	756	806	797	886	736	856	767	793	713	877
U.S. FDA Premarket Approvals (PMA Original & Supplements) — Abbott	65	75	70	50	69	87	53	97	71	66	54	92
U.S. FDA Premarket Approvals (PMA) — Total U.S. MedTech Industry	565	608	567	525	585	588	524	683	538	550	459	656
U.S. FDA Medical Device Recall Events — Abbott	0	4	5	9	4	17	0	14	20	5	7	4
U.S. FDA Enforcement Recall Actions — Abbott	0	4	5	9	4	17	5	9	20	5	8	3
U.S. FDA MAUDE Adverse Event MDR Reports — Abbott Total4	295,931	143,866	29,400	23,684	25,298	23,390	20,979	22,373	25,010	22,310	20,460	22,102
FDA MAUDE MDR Reports — Device Malfunction (Abbott)	285,131	132,390	22,058	16,580	16,531	14,832	12,638	11,987	14,455	12,090	10,656	11,988
FDA MAUDE MDR Reports — Patient Injury (Abbott)	10,413	11,120	7,075	6,857	8,538	8,410	8,212	10,220	10,428	10,069	9,657	9,942
FDA MAUDE MDR Reports — Death (Abbott)	265	354	259	244	227	145	126	162	124	148	141	161
FDA MAUDE Adverse Event MDR Reports — Total MedTech Industry	1,189,467	923,529	811,618	751,012	819,444	632,296	685,251	709,498	699,798	631,546	586,309	573,619
NIH ClinicalTrials.gov — Cumulative Abbott-Sponsored Clinical Studies1
ClinicalTrials.gov — New Abbott Clinical Studies Started	12	4	9	11	10	17	7	14	13	8	14	10
U.S. PPI — Surgical & Medical Instruments Manufacturing (Index)(×)5	163.40	162.90	161.70	159.60	157.80	156.90	157.10	155.20	154.40	154.10	153.60	151.00
U.S. PPI — Surgical Appliances & Supplies Manufacturing (Index)(×)	269.30	263.80	253.80	251.40	249.60	249.50	248.70	245.40	245.10	243.70	240.10	238.50
U.S. PPI — Electromedical & Electrotherapeutic Apparatus (Index)(×)	92.80	92.10	92.00	91.60	90.70	90.30	90.10	89.50	89.30	88.40	88.30	87.80
U.S. CPI — Medical Care Commodities (Index)(×)	404.90	410.40	416.80		417.00	416.50	416.00	412.60	415.90	414.50	408.30	410.10
U.S. CPI — Medical Care Services (Index)(×)	654.70	650.90	647.60		638.40	630.60	623.40	619.60	613.00	611.40	605.80	597.90
U.S. Census QSS — General Medical & Surgical Hospitals Revenue ($M)($M)		47,896	46,674	46,834	46,295	45,370	45,358	45,284	43,778	43,505	43,709	43,264

Reportable Segments Total Operating Earnings ($M)($M)4		1,693	1,345	2,251	2,057	2,052	1,693	1,911	1,859	1,669	1,386	1,780
Medical Devices — Segment Operating Earnings ($M)($M)		1,969	1,893	1,978	1,829	1,796	1,609	1,773	1,513	1,507	1,360	1,501
Diagnostic Products — Segment Operating Earnings ($M)($M)		499	335	609	400	372	359	611	558	430	474	713
Nutritional Products — Segment Operating Earnings ($M)($M)		368	311	386	360	418	394	443	312	373	377	361
Established Pharmaceutical Products — Segment Operating Earnings ($M)($M)		382	365	255	391	346	298	271	380	315	267	254
Medical Devices — Segment Cost of Products Sold ($M)($M)3		1,925	1,814	-12,096	1,767	1,758	1,598	-11,187	1,605	1,627	1,547
Diagnostic Products — Segment Cost of Products Sold ($M)($M)		1,532	1,242	-8,650	1,290	1,224	1,152	-8,666	1,280	1,203	1,188
Nutritional Products — Segment Cost of Products Sold ($M)($M)		1,148	1,089	-8,071	1,223	1,155	1,124	-7,919	1,151	1,148	1,088
Established Pharmaceutical Products — Segment Cost of Products Sold ($M)($M)		650	644	-4,529	714	631	569	-4,263	644	591	584
Medical Devices — Segment Total Assets ($M)($M)7		11,406	10,983	10,689	10,576	10,555	10,034	9,472				9,029
Diagnostic Products — Segment Total Assets ($M)($M)		9,709	9,631	8,273	8,201	8,177	7,840	7,678				7,767
Nutritional Products — Segment Total Assets ($M)($M)		5,278	4,903	4,791	4,891	4,910	4,635	4,404				4,270
Established Pharmaceutical Products — Segment Total Assets ($M)($M)		3,819	3,665	3,540	3,730	3,732	3,448	3,087				3,118
Medical Devices — Segment Depreciation & Amortization ($M)($M)		106	100	99	97	94	88	82	87	87	87
Diagnostic Products — Segment Depreciation & Amortization ($M)($M)		165	144	136	136	135	126	134	129	129	129
Nutritional Products — Segment Depreciation & Amortization ($M)($M)		51	50	42	47	44	42	43	38	39	39
Established Pharmaceutical Products — Segment Depreciation & Amortization ($M)($M)		25	30	25	28	25	23	25	23	24	24
Geographic Revenue — United States ($M)($M)2		5,216	4,274	4,383	4,299	4,276	4,168	4,341	4,202	3,934	3,846	3,949
Long-Lived Assets — United States ($M)($M)				11,900				10,300				8,900
Long-Lived Assets — International ($M)($M)				0				0

Consolidated Net Sales ($M)($M)11		12,593	11,164	11,459	11,369	11,142	10,358	10,974	10,635	10,377	9,964	10,241
Cost of Products Sold ($M)($M)		5,325	4,890	4,922	5,075	4,854	4,468	4,942	4,698	4,603	4,463	4,556
GAAP Gross Margin ($M)($M)	6,544	6,610	5,852	6,115	5,874	5,868	5,470	5,567	5,467	5,303	5,029	5,204
Research & Development Expense ($M)($M)		892	767	735	766	725	716	749	713	698	684	700
Selling, General & Administrative Expense ($M)($M)		4,025	3,740	3,129	3,051	3,091	3,061	2,907	2,895	2,936	2,959	2,724
Operating Earnings ($M)($M)		1,693	1,345	2,251	2,057	2,052	1,693	1,911	1,859	1,669	1,386	1,780
Interest Expense ($M)($M)		351	174	120	121	121	131	136	142	140	141	159
Earnings Before Taxes ($M)($M)		1,524	1,449	2,358	2,180	2,150	1,778	2,030	1,940	1,607	1,436	1,795
Taxes on Earnings ($M)($M)		596	372	582	536	371	453	-7,199	294	305	211	201
Net Earnings ($M)($M)		928	1,077	1,776	1,644	1,779	1,325	9,229	1,646	1,302	1,225	1,594
Diluted Earnings Per Common Share ($/share)($)		0.53	0.61		0.94	1.01	0.76		0.94	0.74	0.70
Weighted-Average Diluted Shares Outstanding (Millions)(M)		1,743	1,747		1,749	1,751	1,747		1,748	1,751	1,750
Total Assets ($M)($M)11		109,215	110,429	86,713	84,181	83,999	81,448	81,414	74,356	73,017	72,467	73,214
Cash & Cash Equivalents ($M)($M)		5,104	6,803	8,522	7,511	6,951	6,532	7,616	7,558	6,987	6,284	6,896
Short-Term Investments ($M)($M)		499	492	417	222	331	312	351	230	232	367	383
Trade Accounts Receivable, Net ($M)($M)		8,599	8,210	7,929	8,138	7,972	7,327	6,925	7,051	6,854	6,605	6,565
Total Inventories ($M)($M)		7,315	6,989	6,488	6,708	6,954	6,639	6,194	6,813	6,814	6,827	6,570
Total Current Assets ($M)($M)		24,517	25,508	25,996	24,839	24,468	23,153	23,656	23,802	23,119	22,376	22,670
Net Property & Equipment ($M)($M)		12,812	12,377	11,816	11,504	11,395	10,932	10,658	10,621	10,233	10,107	10,154
Goodwill ($M)($M)		35,244	35,221	24,035	23,971	23,952	23,359	23,108	23,658	23,308	23,383	23,679
Intangible Assets, Net of Amortization ($M)($M)		17,211	17,875	5,526	5,598	5,920	6,261	6,647	7,352	7,827	8,296	8,815
Total Current Liabilities ($M)($M)		17,814	18,377	16,496	14,582	13,439	13,004	14,157	14,902	13,760	14,021	13,841
Long-Term Debt ($M)($M)		29,603	29,638	9,896	11,596	12,930	12,736	12,625	12,825	13,139	12,576	13,599
Total Shareholders' Investment / Equity ($M)($M)		51,110	52,061	52,130	50,954	50,565	48,811	47,664	39,796	39,318	38,810	38,603
Operating Cash Flow ($M)($M)3		2,488	1,315	3,315	2,787	2,047	1,417	2,868	2,705	1,960	1,025	3,038
Capital Expenditures ($M)($M)		497	399	689	496	502	484	720	556	533	398	755
Dividends Paid ($M)($M)		1,102	1,098	1,030	1,031	1,029	1,026	958	960	961	957	888
Stock-Based Compensation Expense ($M)($M)		168	317	113	120	142	289	111	117	141	304	114

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Core Operational KPI Drivers (Groups 1–4): Flagship Continuous Glucose Monitoring (FreeStyle Libre & Lingo) sales and organic growth, all 7 Medical Devices divisions (Diabetes Care, Electrophysiology, Structural Heart, Rhythm Management, Heart Failure, Vascular, Neuromodulation), all 5 Diagnostics divisions (Core Laboratory, Cancer Diagnostics / Exact Sciences acquired March 2026, Rapid & Molecular Diagnostics, and legacy Rapid/Molecular/Point of Care) + COVID-19 testing sales & ex-COVID base growth, Nutritional Products (Pediatric & Adult + WIC state contracts & NEC reserves), and Established Pharmaceuticals (Key Emerging Markets vs. Other Markets).
Standalone / Parent-Only Assessment (Step 3 & Step 4): Abbott Laboratories files consolidated financial statements under U.S. GAAP (Form 10-K/10-Q) without separate parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Subsidiary operations are captured directly from self-reported filings in Group 7: 74.99%-owned listed Indian subsidiary Abbott India Limited (NSE: ABBOTINDIA, in INR Crores) and 4 UK operating subsidiaries (UK Gender Pay Gap filings).
Period Splitting (Step 4): Missing standalone quarters for CGM revenue (where 10-Q/10-K reported 6M, 9M, and FY cumulative totals) and cash flow statement quarters (Q2–Q4) are derived strictly via 6M − Q1, 9M − 6M, and FY − 9M.

Not shown because recent periods are missing (4)

FreeStyle Libre Global Patient Count (~6M–7M users) — Disclosed only as approximate bounds ('more than 6 million', 'nearly 7 million') in earnings calls/releases; excluded per Step 5 bound rule.
Annual People Reached Globally (>2 billion people / 3 billion lives目标) — Disclosed as bound ('more than 2 billion') in Annual Report / ESG; excluded per Step 5 bound rule.
Scope 3 GHG Emissions by Category (ktCO2e) — Only 1–2 years of complete category disaggregation in ESG 2024; excluded due to insufficient multi-period continuity.
Diagnostics Legacy Subsegments (Rapid Diagnostics, Molecular Diagnostics, Point of Care) post-FY2025Q4 — Combined into 'Rapid and Molecular Diagnostics' starting Q1 2026; legacy series retained through FY2025Q4 and new combined series tracked from Q1 2026.

Data updated 2026-10-29.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Abbott Laboratories (ABT) operating KPIs

KPIs

Every KPI on its own page

Continuous Glucose Monitoring (FreeStyle Libre) & Medical Devices 7 Divisions (Key Chính)

Diagnostics — Core Lab, Cancer Diagnostics (Exact Sciences), Rapid/Molecular & COVID-19 Testing

Nutritional Products — Pediatric & Adult Divisions, WIC State Contracts & Volume/Price

Established Pharmaceuticals (Branded Generics) — Key Emerging Markets vs. Other Markets

Consolidated Volume/Price/FX Decomposition, Gross-to-Net Sales Rebates, Non-GAAP & Footnotes

Global Workforce, Compensation (DEF 14A), 3TG Conflict Minerals (Form SD) & ESG Operations

Subsidiaries Self-Reported Data — Abbott India Limited (NSE: ABBOTINDIA) & UK Operating Subsidiaries

External MedTech Regulatory (openFDA), ClinicalTrials.gov, Federal Contracts & FRED Benchmarks

Reportable Segments & Country Geography Breakdown (Database Context)

Consolidated Financial Statements — Income, Balance Sheet & Cash Flows (Database Context)